Clinical trial readout dates for Definium Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is September 2027.
The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.
| Phase 3 DT120 Generalized Anxiety Disorder · NCT06809595 | August 2026 Primary data collected |
| Phase 3 DT120 Generalized Anxiety Disorder · NCT06741228 | July 2026 Primary data collected |
| Phase 3 DT120 Major Depressive Disorder · NCT06941844 | May 2026 Primary data collected |
| Phase 3 DT120 Major Depressive Disorder · NCT07592689 | September 2027 Recruiting |
Definium Therapeutics Inc. reported $1.05B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-09). Its net loss for that quarter was $51M; at that rate the cash would last about 21 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-09 |